By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The EMEA’s efforts in the area of pediatric medications were assessed, taking into account the quantity of both drugs approved for use in children and pediatric research that supported the Marketing Authorization (MA). Information on medications approved by EMEA was taken from EPARs (European Public Assessment Reports).
ATC codes, indications, orphan status, ages, and characteristics of registrative clinical studies were evaluated, along with the active substance, year of approval, anatomical, therapeutic, and chemical (ATC) codes.33.3% of drugs are permitted for pediatric use.
When different subsets of medicines [drugs for children under 2 years old (23.4%), N-ATC code drugs (6%) and orphan drugs (46.4%)] were taken into account, this percentage either reduced or increased.
The Europe baby medicine market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
A consortium of pediatric specialists in Europe has been launched to concentrate on the creation of novel medications and extra treatments for kids. The Collaborative Network for European Clinical Trials for Children (c4c), also known as conect4children, will include academics from 33 academic institutions, ten industrial partners from 20 European countries, more than 50 third party groups, and over 500 affiliated collaborators.
The partnership seeks to increase Europe’s competitiveness in the production of pediatric pharmaceuticals by utilizing existing expertise and patient access. The c4c network will create a pan-European framework to plan and carry out international pediatric clinical trials throughout Europe while establishing relationships with regulators.
To create medications for uncommon pediatric illnesses and regions with significant medical needs, they will also use new trial designs and quantitative techniques. The partners want to develop procedures that can be used in studies, registries, and comparisons of current medications as well as studies on the natural history of diseases and future treatments.
